rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2010-6-10
|
pubmed:abstractText |
The aim of this study is to evaluate the efficacy and safety of preoperative radiation therapy combined with S-1 and irinotecan (SI) in LARC.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1879-0887
|
pubmed:author |
pubmed-author:AhnJoong BaeJB,
pubmed-author:BaikSeung HyukSH,
pubmed-author:ChoenJae HeeJH,
pubmed-author:ChoiHye JinHJ,
pubmed-author:ChungHyun CheolHC,
pubmed-author:ImJun SeokJS,
pubmed-author:JeungHei-CheulHC,
pubmed-author:KeumKi ChangKC,
pubmed-author:KimHo GeunHG,
pubmed-author:KimNam KyuNK,
pubmed-author:RhaSun YoungSY,
pubmed-author:RohJae KyungJK,
pubmed-author:ShinSang JoonSJ
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
95
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
303-7
|
pubmed:meshHeading |
pubmed-meshheading:20211505-Adult,
pubmed-meshheading:20211505-Aged,
pubmed-meshheading:20211505-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20211505-Camptothecin,
pubmed-meshheading:20211505-Combined Modality Therapy,
pubmed-meshheading:20211505-Disease-Free Survival,
pubmed-meshheading:20211505-Drug Combinations,
pubmed-meshheading:20211505-Female,
pubmed-meshheading:20211505-Humans,
pubmed-meshheading:20211505-Male,
pubmed-meshheading:20211505-Middle Aged,
pubmed-meshheading:20211505-Oxonic Acid,
pubmed-meshheading:20211505-Rectal Neoplasms,
pubmed-meshheading:20211505-Tegafur
|
pubmed:year |
2010
|
pubmed:articleTitle |
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.
|
pubmed:affiliation |
Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu 120-752 Seoul, Republic of Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|